We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
Read MoreHide Full Article
Nevro Corp. (NVRO - Free Report) is well poised for growth on the back of its flagship platform — Senza, and research and development (R&D) capabilities. However, intense competition continues to mar prospects.
The stock has gained 61.3%, compared with the industry’s growth of 20.3% in a year’s time. Further, the S&P 500 Index rallied 15.7% in the same time frame.
Nevro — with a market capitalization of $4.69 billion — is a medical device company that engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. Its beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).
What’s Deterring the Stock?
Nevro faces stiff competition in the Spinal Cord Stimulation market. Per management, the primary competitive factors are company brand recognition, clinical research leadership, and pricing and reimbursement. Consequently, this remains a concern.
Key Catalysts
Nevro’s flagship platform, Senza, has been developed and commercialized for the treatment of chronic pain. The system delivers paresthesia-free HF10 therapy, which is superior compared with the traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain. Further, Nevro recently launched its next product platform, Senza Omnia, in the United States that is expected to provide the company a competitive edge in the near future.
The Senza Omnia has been gaining traction through the first quarter of 2020. Omnia, which is the only SCS platform that can offer high frequency, plus lower frequencies and paired waveforms, received an earlier-than-expected approval in Australia during the first quarter.
In May 2020, the company announced the receipt of CE mark approval for the Senza Omnia Spinal Cord Stimulation (SCS) system. This next-generation SCS system has been created and developed in close consultation with customers to offer a comprehensive solution for chronic pain. This approval is likely to aid Nevro in strengthening its international presence further. In the second quarter of 2020, the company launched Omnia in Europe and Australia and it is ramping efforts in those markets.
Nevro aims to continue improving patient outcomes and expanding patient access to HF10 therapy through enhancements to Senza and development of newer indications.
Through the second quarter, the company continued to invest in R&D to strengthen its product capabilities and expand its total addressable markets with new clinical data and patient indications. On the clinical and regulatory side of things, the company has continued to conduct a plethora of remote clinical studies for its 2 large-scale randomized controlled trials.
Which Way are Estimates Headed?
For 2020, the Zacks Consensus Estimate for revenues is pegged at $362.5 million, indicating a decline of 7.1% from the prior-year quarter. The same for adjusted loss per share stands at $2.95.
Stocks to Consider
Some better-ranked stocks from the broader medical space include West Pharmaceutical Services, Inc. (WST - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and PerkinElmer, Inc. . While PerkinElmer sports a Zacks Rank of 1 (Strong Buy), both Thermo Fisher and West Pharmaceuticals carry a Zacks Rank #2 (Buy). You can seethe complete list of today’s Zacks #1 Rank stocks here.
PerkinElmer has a projected long-term earnings growth rate of 17.4%.
West Pharmaceutical has a projected long-term earnings growth rate of 17.4%.
Thermo Fisher has an estimated long-term earnings growth rate of 15%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
Nevro Corp. (NVRO - Free Report) is well poised for growth on the back of its flagship platform — Senza, and research and development (R&D) capabilities. However, intense competition continues to mar prospects.
The stock has gained 61.3%, compared with the industry’s growth of 20.3% in a year’s time. Further, the S&P 500 Index rallied 15.7% in the same time frame.
Nevro — with a market capitalization of $4.69 billion — is a medical device company that engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. Its beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).
What’s Deterring the Stock?
Nevro faces stiff competition in the Spinal Cord Stimulation market. Per management, the primary competitive factors are company brand recognition, clinical research leadership, and pricing and reimbursement. Consequently, this remains a concern.
Key Catalysts
Nevro’s flagship platform, Senza, has been developed and commercialized for the treatment of chronic pain. The system delivers paresthesia-free HF10 therapy, which is superior compared with the traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain. Further, Nevro recently launched its next product platform, Senza Omnia, in the United States that is expected to provide the company a competitive edge in the near future.
The Senza Omnia has been gaining traction through the first quarter of 2020. Omnia, which is the only SCS platform that can offer high frequency, plus lower frequencies and paired waveforms, received an earlier-than-expected approval in Australia during the first quarter.
In May 2020, the company announced the receipt of CE mark approval for the Senza Omnia Spinal Cord Stimulation (SCS) system. This next-generation SCS system has been created and developed in close consultation with customers to offer a comprehensive solution for chronic pain. This approval is likely to aid Nevro in strengthening its international presence further. In the second quarter of 2020, the company launched Omnia in Europe and Australia and it is ramping efforts in those markets.
Nevro aims to continue improving patient outcomes and expanding patient access to HF10 therapy through enhancements to Senza and development of newer indications.
Through the second quarter, the company continued to invest in R&D to strengthen its product capabilities and expand its total addressable markets with new clinical data and patient indications. On the clinical and regulatory side of things, the company has continued to conduct a plethora of remote clinical studies for its 2 large-scale randomized controlled trials.
Which Way are Estimates Headed?
For 2020, the Zacks Consensus Estimate for revenues is pegged at $362.5 million, indicating a decline of 7.1% from the prior-year quarter. The same for adjusted loss per share stands at $2.95.
Stocks to Consider
Some better-ranked stocks from the broader medical space include West Pharmaceutical Services, Inc. (WST - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and PerkinElmer, Inc. . While PerkinElmer sports a Zacks Rank of 1 (Strong Buy), both Thermo Fisher and West Pharmaceuticals carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PerkinElmer has a projected long-term earnings growth rate of 17.4%.
West Pharmaceutical has a projected long-term earnings growth rate of 17.4%.
Thermo Fisher has an estimated long-term earnings growth rate of 15%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>